(E)-4-(2,4-dichlorophenyl)-2-oxo-3-butenoic acid | 42393-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-4-(2,4-dichlorophenyl)-2-oxo-3-butenoic acid
• 英文别名: (E)-4-(2,4-dichlorophenyl)-2-oxobut-3-enoic acid；(E)-2-oxo-4-(2,4-dichloro-phenyl)-but-3-enoic acid；(3E)-4-(2,4-Dichlorophenyl)-2-oxo-3-butenoic acid
• CAS: 42393-07-7
• 化学式: C₁₀H₆Cl₂O₃
• 分子量: 245.062
• InChiKey: YHVBJAPTZHMQAH-DUXPYHPUSA-N

物化性质

• 熔点：
  138-139 °C(Solv: benzene (71-43-2))
• 沸点：
  391.3±42.0 °C(Predicted)
• 密度：
  1.507±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-4-(2,4-dichlorophenyl)-2-oxo-3-butenoic acid 在 potassium tert-butylate 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 19.0h， 生成 5-Cyano-4-(2,4-dichloro-phenyl)-6-methyl-pyridine-2-carboxylic acid methylamide
  参考文献：
  名称：

  Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases

  摘要：

  公开号：

  EP2308847B1
• 作为产物：
  描述：

  2,4-二氯苯甲醛 、 丙酮酸 在 potassium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 (E)-4-(2,4-dichlorophenyl)-2-oxo-3-butenoic acid
  参考文献：
  名称：

  Direct Asymmetric Hydrogenation of 2-Oxo-4-arylbut-3-enoic Acids

  摘要：

  A challenging direct asymmetric hydrogenation of (E)-2-oxo-4-arylbut-3-enoic acids to give 2-hydroxy-4-arylbutanoic acids (85.4-91.8% ee) was achieved with a Ru catalyst based on SunPhos as the chiral ligand. Further investigation of the reaction revealed that partial isomerization of 2-hydroxy-4-arylbutenoic acids was involved in the hydrogenation process. Employing the reaction conditions to the hydrogenation of 2-oxo-4-phenylbutanoic acid resulted in better enantioselectivity (91.8% ee) and efficiency (TON = 2000, TOF = 200 h(-1)), which offers a useful method for the synthesis of a common intermediate for ACE inhibitors.

  DOI：

  10.1021/jo101084t

文献信息

• 苯基吡啶类化合物及其应用
  申请人：上海医药工业研究院

  公开号：CN107176947B

  公开（公告）日：2019-09-13

  本发明公开了如式Ⅰ所示的苯基吡啶类化合物及其在降糖药物制备中的应用。具体地，本发明公开了式Ⅰ所示的苯基吡啶类化合物或其盐以及其在制备用于治疗和/或预防非胰岛素依赖性糖尿病、高血糖或胰岛素抗性的药物中的应用。本发明的苯基吡啶类化合物及其盐对DPP‑4具有良好的抑制效果，具有良好的市场应用前景；此外，还为DPP‑4抑制剂的研发提供了一个新方向。
• Synthesis of 5-unsubstituted dihydropyrimidinone-4-carboxylates from deep eutectic mixtures
  作者：Sangram Gore、Sundarababu Baskaran、Burkhard König

  DOI：10.3762/bjoc.18.37

  日期：——

  A facile one-pot synthesis of 5-unsubstituted dihydropyrimidinones from β,γ-unsaturated ketoesters in low melting ʟ-(+)-tartaric acid–N,N-dimethylurea mixtures is reported. This solvent-free method is very general and provides easy access to 5-unsubstituted dihydropyrimidinone-4-carboxylate derivatives in good yields.

  报道了一种简便的一锅法合成5-未取代二氢嘧啶酮，其方法是从低熔点ʟ-(+)-酒石酸-N,N-二甲基脲混合物中的β,γ-不饱和酮酯开始。这种无溶剂的方法非常通用，可轻松获得产率良好的5-未取代二氢嘧啶酮-4-羧酸酯衍生物。
• Deracemisation of aryl substituted α-hydroxy esters using Candida parapsilosis ATCC 7330: effect of substrate structure and mechanism
  作者：B. Baskar、N.G. Pandian、K. Priya、Anju Chadha

  DOI：10.1016/j.tet.2005.09.104

  日期：2005.12

  Candida parapsilosis ATCC 7330 was found to be an efficient biocatalyst for the deracemisation of aryl alpha-hydroxy esters (65-85% yield and 90-99% ee). A variety of aryl and aryl substituted alpha-hydroxy esters were synthesized to reflect steric and electronic effects on biocatalytic deracemisation. The mechanism of this biocatalytic deracemisation was found to be stereoinversion. (c) 2005 Elsevier Ltd. All rights reserved.
• Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
  申请人：EMC microcollections GmbH

  公开号：EP2308847B1

  公开（公告）日：2014-04-02
• Direct Asymmetric Hydrogenation of 2-Oxo-4-arylbut-3-enoic Acids
  作者：Lvfeng Zhu、Qinghua Meng、Weizheng Fan、Xiaomin Xie、Zhaoguo Zhang

  DOI：10.1021/jo101084t

  日期：2010.9.3

  A challenging direct asymmetric hydrogenation of (E)-2-oxo-4-arylbut-3-enoic acids to give 2-hydroxy-4-arylbutanoic acids (85.4-91.8% ee) was achieved with a Ru catalyst based on SunPhos as the chiral ligand. Further investigation of the reaction revealed that partial isomerization of 2-hydroxy-4-arylbutenoic acids was involved in the hydrogenation process. Employing the reaction conditions to the hydrogenation of 2-oxo-4-phenylbutanoic acid resulted in better enantioselectivity (91.8% ee) and efficiency (TON = 2000, TOF = 200 h(-1)), which offers a useful method for the synthesis of a common intermediate for ACE inhibitors.